• NKTR-214 prodrug design results in potent immune activation with every 3 week dosing 
1L Melanoma (n=38 Efficacy Evaluable) Overall Response Rate Confirmed ORR (CR+PR)
20 (53%)
12/38 (32%) 100% Reduction Target Lesions 9/38 (24%) Complete Responses
High level of concordance in ORR between independent central radiology (53%) and investigator-assessed 19/38 (50%).
Per protocol, efficacy evaluable is defined as patients with ≥ 1 post baseline scan. 3 patients discontinued prior to 1 st scan due to TEAE [n=1] and Patients Decision [n=2].
Three responders progressed after 6 months of treatment. All three patients sustained tumor control of target lesions (-100%, -100%, -50%) with 2 patients having non-target, new subcutaneous lesions and one patient with new mediastinal lymph node deemed as progression by independent radiology. One patient not represented in plot had target lesions per protocol by Investigator assessment but did not have target lesion at baseline by BICR. Patient achieved non-target SD based on non-target lesion during the study. Patients who discontinued due to a TRAE (blood creatinine increased, stroke) 2 (4.9%)
Median number of cycles = 9. Median duration of exposure = 5.8 months. Per protocol, safety evaluable is defined as patients with ≥ 1 dose of study treatment. • Cytokine related AEs decreased with subsequent cycles of treatment.
• All were low grade (no Grade ≥3 or higher).
• Easily managed with NSAIDs/OTCs.
• No dose delays, dose reductions or study discontinuations due to cytokine related AE's.
• Hydration guidelines effective: no Grade ≥3 TRAEs of hypotension.
• Prodrug design of NKTR-214 accounts for lower frequency of cytokine-related AE's compared to high dose IL-2. Baseline tumor biopsies were evaluated by immunohistochemistry for CD8 cell counts (N=26), and PD-L1 expression (N=26) using the 28-8 method, or tumor mutation burden (TMB, N=12) using the Foundation TMB method. Each patient with matched baseline CD8 and %PD-L1 were plotted as x/y coordinates and correlated with BOR. Each symbol represents an individual patient (CR: N=7, PR: N=9, SD: N=4, and PD: N=6). 
